Press Releases

Press Releases

    Date Title View
    05/06/20
    Summary ToggleHorizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA™ Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-Year 2020 Net Sales Guidance
    04/27/20
    Summary ToggleHorizon Therapeutics plc Announces Availability of PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets in the United States
    PDF Version
    04/15/20
    Summary ToggleHorizon Therapeutics plc to Release First-Quarter 2020 Financial Results and Host Webcast on May 6, 2020
    PDF Version
    04/09/20
    Summary ToggleHorizon Therapeutics plc Named One of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®
    PDF Version
    04/02/20
    Summary ToggleHorizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
    03/31/20
    Summary ToggleTEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
    PDF Version
    03/26/20
    Summary ToggleHorizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities
    PDF Version
    03/03/20
    Summary ToggleHorizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease
    PDF Version
    02/28/20
    Summary ToggleHorizon and Willis Tower Elevate the Need for Rare Disease Innovation on Rare Disease Day
    PDF Version
    02/28/20
    Summary ToggleHorizon Therapeutics plc Partners with EveryLife Foundation to Establish $1 Million #RAREis Scholarship for Adults with Rare Diseases
    PDF Version
    Displaying 11 - 20 of 510 results